Literature DB >> 18834406

Tumor dormancy of primary and secondary cancers.

Taturo Udagawa1.   

Abstract

Tumor dormancy is a phenomenon whereby cancer cells persist below the threshold of diagnostic detection for months to decades. This condition may arise due to either cell cycle arrest or a dynamic equilibrium state in which cell proliferation is in balance with cells undergoing apoptosis. Tumor dormancy is usually a reference to occult cancer cells that persist for an extended period of time after treatment, but primary cancers can also exhibit extended growth plateaus below the limits of detection. For example, autopsies of individuals who died of trauma reveal that most individuals harbor microscopic primary cancers. Mechanisms that operate independently or successively may restrict tumor expansion throughout tumor progression from incipiency to late-stage cancer. Proposed mechanisms include cell cycle withdrawal, immune surveillance, and blocked angiogenesis. The precise mechanisms underlying dormancy remain to be established, and relevant models will have an important impact on diagnostic and therapeutic strategies for treating cancer. This review summarizes the phenomenon of tumor dormancy, experimental models, and potential mechanisms.

Entities:  

Mesh:

Year:  2008        PMID: 18834406     DOI: 10.1111/j.1600-0463.2008.01077.x

Source DB:  PubMed          Journal:  APMIS        ISSN: 0903-4641            Impact factor:   3.205


  27 in total

Review 1.  Metronomic chemotherapy: new rationale for new directions.

Authors:  Eddy Pasquier; Maria Kavallaris; Nicolas André
Journal:  Nat Rev Clin Oncol       Date:  2010-06-08       Impact factor: 66.675

2.  Alterations in nuclear pore architecture allow cancer cell entry into or exit from drug-resistant dormancy.

Authors:  Yayoi Kinoshita; Tamara Kalir; Jamal Rahaman; Peter Dottino; D Stave Kohtz
Journal:  Am J Pathol       Date:  2011-11-07       Impact factor: 4.307

3.  Multifocal lung cancers--clonality vs field cancerization and does it matter?

Authors:  Adi F Gazdar; John D Minna
Journal:  J Natl Cancer Inst       Date:  2009-04-07       Impact factor: 13.506

Review 4.  Do statins cause diabetes?

Authors:  Mark R Goldstein; Luca Mascitelli
Journal:  Curr Diab Rep       Date:  2013-06       Impact factor: 4.810

Review 5.  Epithelial-Mesenchymal Transition Programs and Cancer Stem Cell Phenotypes: Mediators of Breast Cancer Therapy Resistance.

Authors:  Alex J Gooding; William P Schiemann
Journal:  Mol Cancer Res       Date:  2020-06-05       Impact factor: 5.852

6.  Biological resonance for cancer metastasis, a new hypothesis based on comparisons between primary cancers and metastases.

Authors:  Dongwei Gao; Sha Li
Journal:  Cancer Microenviron       Date:  2013-11-10

7.  "The development tumor model" to study and monitor the entire progression of both primary and metastatic tumors.

Authors:  Enrico Brognaro
Journal:  Tumour Biol       Date:  2013-11-10

8.  Modeling progression in radiation-induced lung adenocarcinomas.

Authors:  Hatim Fakir; Werner Hofmann; Rainer K Sachs
Journal:  Radiat Environ Biophys       Date:  2010-01-08       Impact factor: 1.925

Review 9.  Dormancy in solid tumors: implications for prostate cancer.

Authors:  Nazanin S Ruppender; Colm Morrissey; Paul H Lange; Robert L Vessella
Journal:  Cancer Metastasis Rev       Date:  2013-12       Impact factor: 9.264

10.  Spontaneous reversion of the angiogenic phenotype to a nonangiogenic and dormant state in human tumors.

Authors:  Michael S Rogers; Katherine Novak; David Zurakowski; Lorna M Cryan; Anna Blois; Eugene Lifshits; Trond H Bø; Anne M Oyan; Elise R Bender; Michael Lampa; Soo-Young Kang; Kamila Naxerova; Karl-Henning Kalland; Oddbjorn Straume; Lars A Akslen; Randolph S Watnick; Judah Folkman; George N Naumov
Journal:  Mol Cancer Res       Date:  2014-02-26       Impact factor: 5.852

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.